97 related articles for article (PubMed ID: 8708409)
21. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
Nájera I; Richman DD; Olivares I; Rojas JM; Peinado MA; Perucho M; Nájera R; López-Galíndez C
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
[TBL] [Abstract][Full Text] [Related]
22. Long-term persistence of AZT-resistance mutations in the plasma HIV-1 of patients removed from AZT therapy.
Smith MS; Koerber KL; Pagano JS
Leukemia; 1994 Apr; 8 Suppl 1():S179-82. PubMed ID: 8152287
[TBL] [Abstract][Full Text] [Related]
23. 3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1.
Mansky LM; Bernard LC
J Virol; 2000 Oct; 74(20):9532-9. PubMed ID: 11000223
[TBL] [Abstract][Full Text] [Related]
24. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
Kerr SG; Anderson KS
Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
[TBL] [Abstract][Full Text] [Related]
25. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O
Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the antiviral activities of 3'-azido-3'-deoxythymidine (AZT) and gossylic iminolactone (GIL) against clinical isolates of HIV-1.
Royer RE; Mills RG; Young SA; Vander Jagt DL
Pharmacol Res; 1995 Jan; 31(1):49-52. PubMed ID: 7540302
[TBL] [Abstract][Full Text] [Related]
27. In vivo prevalence of azidothymidine (AZT) resistance mutations in an AIDS patient before and after AZT therapy.
Fitzgibbon JE; Howell RM; Schwartzer TA; Gocke DJ; Dubin DT
AIDS Res Hum Retroviruses; 1991 Mar; 7(3):265-9. PubMed ID: 2064825
[TBL] [Abstract][Full Text] [Related]
28. Application of a colorimetric chain-termination assay for characterization of reverse transcriptase from 3'-azido-2',3'-deoxythymidine-resistant HIV isolates.
Shao XW; Hjalmarsson S; Lennerstrand J; Svennerholm B; Blomberg J; Källander CF; Gronowitz JS
Biotechnol Appl Biochem; 2002 Jun; 35(3):155-64. PubMed ID: 12074693
[TBL] [Abstract][Full Text] [Related]
29. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
30. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.
Kellam P; Boucher CA; Tijnagel JM; Larder BA
J Gen Virol; 1994 Feb; 75 ( Pt 2)():341-51. PubMed ID: 7509370
[TBL] [Abstract][Full Text] [Related]
31. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
[TBL] [Abstract][Full Text] [Related]
32. Natural resistance of human immunodeficiency virus type 2 to zidovudine.
Reid P; MacInnes H; Cong ME; Heneine W; García-Lerma JG
Virology; 2005 Jun; 336(2):251-64. PubMed ID: 15892966
[TBL] [Abstract][Full Text] [Related]
33. Different properties of wild type and drug-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase in vitro.
Ijichi K; Fujiwara M; Shigeta S; Konno K; Yokota T; Baba M
Microbiol Immunol; 1996; 40(5):353-8. PubMed ID: 8805099
[TBL] [Abstract][Full Text] [Related]
34. Sequence analysis of an HIV-1 isolate which displays unusually high-level AZT resistance in vitro.
Muckenthaler M; Gunkel N; Levantis P; Broadhurst K; Goh B; Colvin B; Forster G; Jackson GG; Oxford JS
J Med Virol; 1992 Feb; 36(2):79-83. PubMed ID: 1374791
[TBL] [Abstract][Full Text] [Related]
35. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
Sharma PL; Chatis PA; Dogon AL; Mayers DL; McCutchan FE; Page C; Crumpacker CS
Virology; 1996 Sep; 223(2):365-9. PubMed ID: 8806572
[TBL] [Abstract][Full Text] [Related]
36. Implication of the tRNA initiation step for human immunodeficiency virus type 1 reverse transcriptase in the mechanism of 3'-azido-3'-deoxythymidine (AZT) resistance.
Vaccaro JA; Anderson KS
Biochemistry; 1998 Oct; 37(40):14189-94. PubMed ID: 9760256
[TBL] [Abstract][Full Text] [Related]
37. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
38. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.
Shirasaka T; Kavlick MF; Ueno T; Gao WY; Kojima E; Alcaide ML; Chokekijchai S; Roy BM; Arnold E; Yarchoan R
Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2398-402. PubMed ID: 7534421
[TBL] [Abstract][Full Text] [Related]
39. [Resistance of human immunodeficiency virus (HIV) to zidovudine. Genotypic analysis in strains isolated from Chilean patients].
Vial PA; Vial C; Abarca K; Noriega M; Jiménez G; Labarca J; Gasep J; Palacios O; Pérez C; Acuña G
Rev Med Chil; 1998 Jan; 126(1):17-26. PubMed ID: 9629750
[TBL] [Abstract][Full Text] [Related]
40. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Larder BA; Kellam P; Kemp SD
Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
